Q-omics provides the consensus-scored CYP20A1 profile across patient tissues and cancer cell-line models. CYP20A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CYP20A1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CYP20A1 protein abundance shows 21,660 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, THCA, and GBM as cancer lineages where CYP20A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP20A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP20A1 survival associations across molecular data types. CYP20A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP20A1 RNA expression–survival associations across cancer types. High CYP20A1 expression shows unfavorable associations in ACC, UVM and LGG, but favorable associations in LUAD, KIRC and THYM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for CYP20A1 RNA expression.
This table summarizes CYP20A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYP20A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP20A1 shows lower tumor expression in THCA, KICH, BLCA, LUSC and KIRC and higher tumor expression in LIHC. The THCA box plot shows higher CYP20A1 RNA expression in normal versus tumor tissue (log2 FC = −0.713, t-test p < 0.001).
This table shows molecular features associated with CYP20A1 in patient tissues and cancer cell lines. In patient samples, CYP20A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP20A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
